Measure | Baseline | Daily | Every 3 days | End of 6 day cycle | End of trial |
---|---|---|---|---|---|
Demographics | x | Â | Â | Â | Â |
Vital Signs | x | Â | Â | Â | Â |
Routine blood test | x | Â | Â | Â | Â |
AKPS | x | Â | Â | Â | x1 |
EORTC-QLQC15-PAL core items | x | Â | Â | Â | x |
Adverse Event Reporting1 | x | x | x | x | x |
Xerostomia NRS | Â | x | Â | Â | Â |
Xerostomia inventory | Â | x | Â | Â | Â |
Number of breakthrough salivary substitute uses | Â | x | Â | Â | Â |
Dysphagia | Â | x | Â | Â | Â |
Dysgeusia | Â | x | Â | Â | Â |
Changes in xerostomia related medications | Â | x | Â | Â | Â |
OHIP | Â | Â | x | Â | Â |
PGIC | Â | Â | x | Â | Â |